# Remedy Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remedy-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.remedypharmaceuticals.com
- Total disclosed funding: $3.9M
- Latest round: Series B (May 22, 2012)
- Investors on record: 1

## About

Remedy Pharmaceuticals, Inc. focuses on developing innovative therapeutics, particularly its investigational drug CIRARA, aimed at treating acute ischemic stroke and enhancing neurological recovery in patients.Founded in 2004, Remedy Pharmaceuticals, Inc. is based in New York, US. The company specializes in creating therapeutics, particularly for acute ischemic stroke. In May 2017, Biogen, Inc. acquired Remedy Pharmaceuticals' asset CIRARA for USD 120 mn. David Geliebter is the founder of the company, who has a history of contributing to the pharmaceutical industry.Remedy Pharmaceuticals Inc. specializes in the development of innovative therapeutics, with a primary focus on its flagship product, CIRARA, which is designed for the treatment of acute ischemic stroke. CIRARA aims to enhance neurological recovery in patients who have suffered a stroke, utilizing a unique mechanism that targets the underlying pathophysiology of the condition. The company seeks to address critical unmet medical needs by providing effective treatments to healthcare providers and patients navigating the aftermath of a stroke event. Remedy Pharmaceuticals targets healthcare institutions, including hospitals and rehabilitation centers, as its primary clients, while the end-users are the patients who benefit from the therapeutic interventions. The geographical markets for CIRARA include North America, Europe, and select regions in Asia, where clinical trials and subsequent product launches are strategically planned.Remedy Pharmaceuticals generates revenue primarily through partnerships with healthcare providers and institutions involved in clinical trials and research studies related to its investigational drugs. The transaction structure typically involves agreements with hospitals and research centers that participate in the development and trial phases, allowing for the collection of data and feedback on CIRARA’s efficacy and safety. Revenue generation may be structured through milestone payments contingent on trial progression, as well as potential future licensing agreements following successful regulatory approvals. The company's business model also considers direct to consumer pathways once products receive market authorization, expanding access to its therapeutics. Specific pricing plans for CIRARA and any associated products will be determined post-approval, aligning with industry standards and market demand.Remedy Pharmaceuticals plans to leverage the recent acquisition of CIRARA by Biogen, Inc. to bolster its presence in the healthcare market. The funding from the Trade Sale of USD 120 mn will support the ongoing development and clinical trials for CIRARA, with expansion efforts targeted towards North America, Europe, and select regions in Asia by the end of 2023. Further product development initiatives are anticipated as the company seeks to enhance its therapeutic offerings.

## Funding rounds

- Series B, May 22, 2012, $2.7M — Embark Healthcare
- Series A, Mar 6, 2012, $0.3M — Embark Healthcare
- Series A, Nov 22, 2011, $0.5M — Embark Healthcare
- Series A, Sep 22, 2010, $0.4M — Embark Healthcare

## Investors

- Embark Healthcare (https://capitalatlas.ai/funds/embark-healthcare) — Series A, Series B